Brief: Travere Therapeutics Provides Update On FDA Advisory Committee Meeting For FILSPARI In FSGS
10/09/2025 12:55
Sept 10 (Reuters) - Travere Therapeutics Inc TVTX.O: TRAVERE THERAPEUTICS PROVIDES UPDATE ON FDA ADVISORY COMMITTEE MEETING FOR FILSPARI® (SPARSENTAN) IN FSGS TRAVERE THERAPEUTICS INC - FDA NO LONGER REQUIRES ADVISORY COMMITTEE FOR FILSPARI SNDA REVIEW TRAVERE THERAPEUTICS INC - FDA PDUFA DATE FOR FILSPARI SET FOR JANUARY 13, 2026 Source text: ID:nBw7fSLHPa Further company coverage: TVTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule